diabetes mellitius cells and molecules clinical application presented 9/6/02 by m. grant ervin...

11
DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Upload: brett-cannon

Post on 03-Jan-2016

212 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

DIABETES MELLITIUS

Cells and Molecules

Clinical Application

Presented 9/6/02

By

M. Grant Ervin MD,MHPE,FACEP

Page 2: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Objectives

• Correlate clinical presentation of patient with DKA with occurrences on cellular level

• Describe mechanisms by which glucagon and insulin regulate glycolysis

• Discuss therapeutic measures used to treat the patient in DKA and the cellular impact

Page 3: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

A 45 year old male is brought into the ED c/o increased thirst, dizziness, weakness for the past

week. He denies any medical problems, medications, allergies.

BP – 100/60, RR-24, HR – 120, Temp.99.9 F

Page 4: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

What are the abnormalities?

• Thirst

• Weakness

• Low blood pressure

• Fast heart rate

• Fast respiratory rate

Page 5: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Simultaneous Diagnostic, Therapeutic, and Rescuscitative

Measures

Pulse OxEKGIV line, blood for I-stat, extra tubes to be

determinedCardiac monitor, BP monitorPhysical Exam significant dry mucus

membranes and abnormal vital signs as stated

Page 6: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Causes of Elevated Anion Gap Metabolic Acidosis

• Carbon monoxide/cyanide exposure

• Alcohol• Touluene• Methanol• uremia

• DKA• Paraldehyde ingestion• Isoniazid/Iron• Lactic acidosis• Ehtylene glycol• salicylates

Page 7: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Cellular Correlations

• Elevated glucose levels secondary to decreased insulin, liver has diminished enymatic capacity to remove glucose

• Decreased glucokinase activity• Loss of insulin’s action on key enzymes of

glycogenesis and the glycolytic pathway• Liver stuck in gluconeogenesis fueled by

substrate from body protein degradation

Page 8: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Cellular Correlations (con.)

• Muscle fails to take up glucose with decreased insulin

• Adipose tissue is stimulated to lipolysis due to low insulin/glucagon ration

• Leads to increased blood levels fatty acids• Accelerated ketone body production• Metabolic acidosis• Increase respiratory rate is trying to correct

acidosis

Page 9: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Overall metabolism is stuck in every tissue continuing its catabolic state producing

more fuel despite increase glucose. Insulin/ glucagon

ration is unbalanced

Page 10: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Therapeutic Measures

• Fluids

• Insulin

• Correct electrolyte deficiencies

• Look for precipitating causes

Page 11: DIABETES MELLITIUS Cells and Molecules Clinical Application Presented 9/6/02 By M. Grant Ervin MD,MHPE,FACEP

Summary

• In Insulin Dependent and Non-Insulin Dependent Diabetes the insulin/ glucagon ratio is vital in intracellular glucose control

• Therapeutic measures are directly tied to what is occurring on a cellular level